Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Stock Price:
$0.980 USD
-0.040 (-3.92%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed
After-hours: $0.990 +0.010 (0.98%) Oct 20, 7:46 PM
Key Info
| Market Cap |
80.08M |
| Revenue (ttm) |
7.21M |
| Net Income (ttm) |
-115.13M |
| Shares Out |
81.71M |
| EPS (ttm) |
-1.70 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 20, 2020 |
| Last Price |
$0.980 |
| Previous Close |
$1.020 |
| Change ($) |
-0.040 |
| Change (%) |
-3.92% |
| Day's Open |
1.010 |
| Day's Range |
0.921 - 1.030 |
| Day's Volume |
5,834,421 |
| 52-Week Range |
0.920 - 9.780 |
More Stats
| Market Cap |
80.08M |
| Enterprise Value |
25.20M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
81.71M |
| Float |
80.25M |
| EPS (basic) |
-1.68 |
| EPS (diluted) |
-1.70 |
| FCF / Share |
-1.31 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
34.72M |
| Short Ratio |
4.08 |
| Short % of Float |
43.27% |
| Beta |
1.83 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
11.10 |
| PB Ratio |
1.87 |
| Revenue |
7.21M |
| Operating Income |
-120.31M |
| Net Income |
-115.13M |
| Free Cash Flow |
-96.82M |
| Net Cash |
54.88M |
| Net Cash / Share |
0.67 |
| Gross Margin |
-741.31% |
| Operating Margin |
-1,668.27% |
| Profit Margin |
-1,596.50% |
| FCF Margin |
-1,342.57% |
| ROA |
-82.52% |
| ROE |
-240.39% |
| ROIC |
2,013.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
1 |
| Overweight |
0 |
| Hold |
5 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$1.88*
(91.84% upside)
Low
1.22
Current: $0.980
High
3.00
Target: 1.88
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 36.14 | 4.82 | 2.44 | 1.91 | 0.65 | - | - |
| Revenue Growth | 649.51% | 97.62% | 27.66% | 194.8% | - | - | - |
| Gross Profit | 36.14 | 4.82 | 2.44 | 1.91 | 0.65 | - | - |
| Operating Income | -77.10 | -56.75 | -32.56 | -19.99 | -8.85 | -2.65 | -0.56 |
| Net Income | -71.45 | -55.67 | -32.42 | -20.00 | -8.85 | -2.54 | -0.60 |
| Shares Outstanding | 63.90 | 57.00 | 50.18 | 41.14 | 31.35 | 20.16 | 6.96 |
| Earnings Per Share | -1.12 | -0.98 | -0.65 | -0.49 | -0.28 | -0.13 | -0.09 |
| Operating Cash Flow | -45.72 | -30.07 | -27.80 | -13.57 | -4.62 | -2.36 | -0.37 |
| Capital Expenditures | -2.74 | -2.30 | -0.71 | -0.35 | -0.11 | -0.06 | - |
| Free Cash Flow | -48.46 | -32.37 | -28.50 | -13.92 | -4.74 | -2.43 | -0.37 |
| Cash & Equivalents | 31.75 | 41.75 | 62.70 | 15.19 | 12.37 | 6.28 | 0.30 |
| Total Debt | 9.45 | 0.39 | 0.33 | 0.27 | 0.16 | 0.14 | 0.64 |
| Net Cash / Debt | 22.30 | 41.35 | 62.36 | 14.92 | 12.21 | 6.13 | -0.34 |
| Assets | 49.14 | 46.99 | 66.98 | 17.89 | 12.88 | 6.60 | 0.31 |
| Liabilities | 42.98 | 19.47 | 9.19 | 8.97 | 3.89 | 0.74 | 0.98 |
| Book Value | 6.16 | 27.52 | 57.78 | 8.92 | 8.99 | 5.86 | -1.78 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Corbus Pharmaceuticals Holdings, Inc. |
| Country |
United States |
| Employees |
141 |
| CEO |
Yuval Cohen |
Stock Information
| Ticker Symbol |
CRBP |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CRBP |
Description
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Company for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.